Prof. Zalcberg has been the Director of the Division of Haematology and Medical Oncology at the Peter MacCallum Cancer Centre since 1997 and was appointed Chief Medical Officer in 2007. He is a practising clinician specializing in gastrointestinal cancer and is interested in translational research and new drug development. Prof. Zalcberg is a founding member and current Chair of the Board of the Australasian Gastrointestinal Trials Group. He has advised a number of national and multinational pharmaceutical companies, served on the CSIRO Pharmaceuticals & Human Health Sector Advisory Committee. Previously, he was Director of Medical Oncology at the Heidelberg Repatriation Hospital, Director for Cancer Services at the Austin and Repatriation Medical Centre, and Board member of Progen Pharmaceuticals Ltd. (ASX: PCL).

Dr. Sweeney was an Internal Medicine resident at Gundersen Lutheran Medical Center, USA from 1994 to 1997 and a Fellow in Hematology/Oncology at Indiana University Medical Center, USA from 1997 to 2000. He is certified by the American Board in Medical Oncology and has held faculty appointments at Indiana University and Royal Adelaide Hospital. He joined the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute in 2009 and is a member of several American organisations in the area of clinical cancer research. Dr. Sweeney has served on the Program Committee and the Cancer Education Committee of the American Society of Clinical Oncology and has been on the Editorial Board for its publication Journal of Clinical Oncology. He has received peer reviewed funding from the National Institutes of Health and the Department of Defense, Lance Armstrong Foundation, and PhRMA and served on the Scientific Advisory Boards of biotech companies in Australia and the USA.

Dr. Bertram Illert is Head of Department for General, Visceral and Pediatric Surgery at the Sana Kliniken Ostholstein in Germany, before which he held an appointment at the University Hospital and Medical School/Department of Surgery in Würzburg Germany. He is a specialist in visceral, abdominal and cancer surgery , particularly of the upper gastrointestinal (GI) tract. His scientific work and research activities focus on disseminated tumour cells in solid tumors of the GI tract, gastric cancer and antibody treatment, for which he has developed an animal model for preclinical studies. Dr Illert was principal investigator in the first study of gastric cancer patients with the human monoclonal antibody PAT-SC1. He is a member of various medical and scientific societies including the German Surgical Society, German Society of General and Visceral Surgery and the German Cancer Society.

Mr. Iverson is a consultant on the development and writing of manufacturing sections for IND applications to the FDA including for at least 10 approved biologics, and several antibody-based products. Mr. Iverson previously held senior positions at Corixa Corporation (Vice President, Process Development); Coulter Pharmaceutical (Vice President, Manufacturing during development of Bexxar); Immunex (Director of Operational Project Management, responsible for Enbrel); and Genentech, Inc. (Senior Technical Operator, Fermentation, with main responsibility for the establishment of cell culture facilities).

Mr. Gagnon is one of the leading experts in protein and virus purification, best known as author of the book Purification Tools for Monoclonal Antibodies. Mr. Gagnon has contributed chapters to many other books, and more than 50 articles and presentations addressing various aspects of protein and virus purification. He is a member of editorial advisory boards for Genetic Engineering News, BioProcess International, and Bioprocessing Journal, and scientific advisory boards for the International Conference on Hydroxyapatite and the International Monolith Symposia, among others. In the laboratory, Mr. Gagnon evaluates new chromatography materials, develops purification procedures, and pursues other scientific interests.

Dr. Brandlein joined Patrys at the time of the OncoMab GmbH and University of Würzburg asset acquisitions. Together with Prof. Peter Vollmers co-founder of OncoMab, Dr. Brandlein has worked for over a decade on the capture, production and characterization of anti-cancer natural human monoclonal antibodies. Dr. Brandlein’s team will further characterise and develop Patrys' cancer pipeline through an extensive and long-term sponsored research and consulting agreement with the University of Würzburg